LipoScience Added to the Russell 3000(R) & 2000(R) Indices

RALEIGH, N.C., April 1, 2013 (GLOBE NEWSWIRE) -- LipoScience, Inc. (Nasdaq:LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of patient care, today announced that its common stock has been selected for inclusion in the Russell 3000® Index and its subset, the Russell 2000® Index, effective as of March 28, 2013. The Russell Indices provide a comprehensive and unbiased barometer of stock performance in the U.S. equity markets. The Russell Indices are completely reconstituted annually to ensure that new and growing equities are reflected.

"Being added to the Russell Indices, particularly within three months of our initial public offering, is an important step in highlighting LipoScience's status as a public company with a meaningful market capitalization," said Richard O. Brajer, President and Chief Executive Officer.

The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies, representing approximately 98% of the investable U.S. equity market. Membership in the Russell 3000 means automatic inclusion in either the large-cap Russell 1000® Index or small-cap Russell 2000® Index. The largest 1,000 companies in the ranking based on their market capitalization comprise the Russell 1000 Index, while the remaining 2,000 companies become the Russell 2000 Index. The Russell 2000 represents approximately 10% of the total market capitalization of the Russell 3000 Index.

About LipoScience, Inc.

LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 9 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, the Vantera® system, has been cleared by the FDA and will be placed with national and regional clinical laboratories. It requires no previous knowledge of NMR technology to operate and has been designed to significantly simplify complex technology through ease of use and walk-away automation.

LipoScience is driving toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit and

CONTACT: Investor Relations ICR, Inc. Bob Yedid Senior Vice President 646-277-1247 LipoScience, Inc. Tori Hall (919) 256-1046

Source:LipoScience, Inc.